Gaithersburg, Maryland, USA and Shin - Yokohama, Japan - MEDINET Co. Ltd., (TSE: #2370) and MaxCyte, Inc., announce the publication of the results of their scientific collaboration demonstrating that the use of MaxCytes cell loading technology results in 5 - 20 fold enhancement in potency of dendritic cell vaccines. The manuscript entitled Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL was published in the journal International Immunopharmacology and can be accessed online at http://dx.doi.org/10.1016/j.intimp.2013.01.009.
"This publication provides clear scientific evidence of MEDINETs leadership position in bringing advanced immunotherapies to cancer patients in Japan, says Mr. Yoshiji Kimura, MEDINET's Chief Executive Officer, "and will enhance our ability to provide the highest quality cancer immuno-cell therapies through our expanding network of Contracted Medical Institutions."
"MEDINET is the leader of the world in cell-based therapies, with world-class expertise in immunotherapeutics," says Douglas A. Doerfler, President and Chief Executive Officer of MaxCyte, "and we look forward to continuing to build on our strong and long-standing partnership."
MEDINET has previously entered into an exclusive license agreement to use MaxCyte's proprietary cell loading system to support clinical studies and commercialize treatment of cancer patients; and subsequently expanded the license to additional Asia-Pacific countries. MEDINET is currently marketing its cancer immunotherapy service in Japan and the largest provider in the country.